arrow
R

Ryosuke Oki

Tokushima University
H指数:10
被引数:432

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

LYMPHOVASCULAR INVASION AND NODAL POSITIVITY AS USEFUL MARKERS FOR SELECTING CANDIDATES FOR ADJUVANT NIVOLUMAB IN HIGH-RISK MUSCLE-INVASIVE UROTHELIAL CARCINOMA

淋巴血管浸润和淋巴结阳性作为选择高危肌层浸润性尿路上皮癌患者接受辅助纳武利尤单抗治疗的有用标志物

2026-05-010
PRE
An R83W mutation in Rab3A causes autosomal-dominant cerebellar ataxia

Rab3A基因中的R83W突变导致常染色体显性小脑共济失调

2026-01-010
PRE
NTRK-rearranged soft tissue sarcoma that originated from the head and neck with a robust response to the TRK inhibitor larotrectinib

NTRK重排的头颈部软组织肉瘤,其对TRK抑制剂larotrectinib表现出显著反应

2025-12-010
PRE
The first case of GOLGA5-RET fusion-positive malignant spindle cell sarcoma of the head and neck responsive to selpercatinib

头颈部GOLGA5-RET融合阳性恶性梭形细胞肉瘤对selpercatinib有反应的首例病例。

2025-09-010
PRE
Sporadic medullary thyroid carcinoma with a rare RET transmembrane domain mutation (A641R) that responds to selpercatinib

散发性髓样甲状腺癌伴罕见RET跨膜域突变(A641R),并对塞尔帕卡替尼有反应

2025-09-010
OAAI
Safety and tolerability of bosutinib in patients with amyotrophic lateral sclerosis (iDReAM study): A multicentre, open-label, dose-escalation phase 1 trial
2022-11-0118
OAAI
A proposed clinical scoring system for initiation of lenvatinib treatment in radioiodine-refractory thyroid cancer patients

在放射性碘难治性甲状腺癌患者中启动来伐替尼治疗的拟议临床评分系统

2022-01-287
PRE
A phase I dose escalation study of bosutinib for amyotrophic lateral sclerosis: Induced pluripotent stem cell-based drug repurposing for amyotrophic lateral sclerosis medicine (IDREAM) study
2021-10-010
PRE
Phenotype variability and allelic heterogeneity in KMT2B-Associated disease
2018-07-0136
PREAI